<DOC>
	<DOCNO>NCT00439972</DOCNO>
	<brief_summary>The purpose study compare effect oral versus patch administration hormonal contraception hormone sensitive protein lipoprotein , clot factor inflammatory protein well blood sugar insulin level , antioxidant status flow-mediated dilation arm forearm vessel . The hypothesis oral administration contraceptive hormone result high plasma level estrogen sensitive protein originate liver patch administration contraceptive hormone result great systemic effect estrogen vascular reactivity antioxidant status .</brief_summary>
	<brief_title>Oral Versus Patch Hormonal Contraceptive Effects Metabolism , Clotting , Inflammatory Factors Vascular Reactivity</brief_title>
	<detailed_description>Study Rationale : The metabolic effect hormonal contraceptive differ administered oral systemic route . The oral route magnifies hepatic production hormone sensitive protein include lipoprotein , clot factor inflammatory protein CRP . These effect due first pass hormone liver portal circulation . The first pas hepatic effect also reduce systemic exposure orally administer estrogen progestin , due glucuronidation sulfation sex hormone excretion bile . Systemic administration patch analogous physiologic hormone release ovary , avoids first pas effect peripheral tissue expose high hormone concentration oral administration . Conversely , liver may lower exposure hormone patch administration oral administration . With respect extend cycle ( 2-month ) patch contraception formulation study , similar question may ask metabolic , inflammatory vascular effect regimen compare one-month cycle . The purpose research : 1. measure plasma estrogen progestin level observe formulation physiological parameter affect vascular health include lipid , glucose insulin , redox state , clot inflammatory factor , vascular reactivity ; 2. study relationship hormone physiological parameter among three regimen . The underlying rationale net effect estrogen-progestin combination function dose biological effect hormone effect differ route administration . Study Design : Three contraception regimen compare open label , randomize , crossover design . The three regimen Ortho-Cyclen速 standard reference oral contraceptive , Ortho Evra速 patch formulation , investigational two month patch formulation . The two month patch formulation consist apply Ortho Evra速 7 week row 8th week compare 3 week patch application 4th week standard patch cycle . Subjects take hormonal regimen two month . Eligible subject initial one-month run-in period Ortho-Cyclen速 . In addition wash previous hormone exposure , washout serve compliance hurdle help select subject willing undergo discipline study . Washouts treatment perform order provide continuous contraception study subject facilitate compliance subject randomize study . As treatment period last two month , first month two-month treatment period consider washout previous treatment protocol . The second month two-month treatment period investigative month . Plasma hormone monitor second month two month period ethinyl estradiol norelgestromin . Norelgestromin primary active metabolite norgestimate metabolism . Clotting parameter measure monitor previous study desogestrel ( D ) vs. levonorgestrel ( L ) contraceptive comparison nearly equal estrogen exposures 9 month . In study , PT PTT increase equally pre-treatment baseline , factor V decrease ( D ) increase ( L ) , free protein S decrease ( D ) change ( L ) . The impression study change internally compensate . PAI-1 , inhibitor plasminogen activation , also measure . These measure 1 , 7 , 21 28 day investigative month . Inflammatory parameter include highly sensitive C-reactive protein ( hsCRP ) , hepatic origin , serum amyloid A ( SAA ) , vary parallel CRP metabolic syndrome transport almost entirely HDL . SAA transport HDL consider barometer impaired HDL function , occur inflammatory state . These measurement obtain day 1 21 . Antioxidant status relate inflammatory metabolic stress additional interest light current NIH NICHD study examine change oxidant stress menstrual cycle . The primary parameter use total antioxidant capacity ( TOAC ) . Several parameter plasma redox status measure interesting trend detect . These parameter also measure day 1 21 respective cycle . We previously describe antioxidant effect estrogen prooxidant effect progestin difference among progestin vitro system . The lipoprotein measure select standard lipid profile consist triglyceride , cholesterol , HDL cholesterol measure precipitation estimation LDL Friedwald algorithm . The HDL2 HDL3 sub-fractions apoproteins AI AII sensitive measure estrogen-progestin balance , sex-hormone binding globulin ( SHBG ) . Lipoprotein lipid , HDL sub-fractions SHBG measure 1 , 7 , 21 28 day . The apoproteins measure day 1 21 . We measure vascular reactivity arterial ischemia two way , brachial artery reactivity venous plethysmography . Both technique sensitive nitric oxide mediate vascular dilation . Both procedure do without nitroglycerin step . Differences flow mediate dilation arterial compliance describe normal menstrual cycle , sensitive differ biologic effect estrogen progestin respective contraceptive cycle . We expect vasodilatory response ischemia represent net oppose biologic effect estrogen progestin , hormone-sensitive plasma protein . These measurement make day 21 second month three treatment arm , day 21 time maximum hormone exposure three regimen . The subject 's overall satisfaction hormonal regimen quantify daily diary along record menstrual history .</detailed_description>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<mesh_term>Ortho Evra</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<criteria>1 . Willing participate crossover design study biweekly weekly clinic visit second , fourth sixth month . 2 . Healthy woman within age range 18 50 year inclusive sexually active risk pregnancy . 1 . Blood pressure 140/90 mmHg 2 . Glucose great 126 mg/dL diabetes mellitus 3 . Triglyceride great 300 mg/dL 4 . Body mass index ( BMI ) great 30 kg/m2 great 18.5 kg/m2 5 . Current past history thrombophlebitis , deep vein thrombosis thromboembolic disorder . 6 . Current past history cerebrovascular coronary artery disease . 7 . Presence valvular heart disease complication . 8 . Major surgery prolong immobilization . 9 . Known suspected carcinoma breast personal history breast cancer . 10 . Carcinoma endometrium know suspected estrogendependent neoplasia . 11 . Undiagnosed abnormal genital bleeding . 12 . History cholestatic jaundice pregnancy history jaundice prior hormonal contraceptive use . 13 . Acute chronic hepatocellular disease abnormal liver function . Hepatic adenoma carcinoma . 14 . Any active liver renal disease . 15 . Untreated thyroid disease . 16 . Migraine headaches focal neurological symptom . 17 . Known suspected pregnancy currently breast feed . 18 . Alcohol intake one drink per day 19 . Cigarette smoke 20 . Depression psychiatric illness 21 . Any lipid lowering blood pressure lower medication 22 . Any illegal drug use 23 . Nonsteroidal antiinflammatory drug ( NSAID ) aspirin use 5 day prior vascular reactivity study . 24 . Antioxidant supplement ( stable multivitamin use allow ) 25 . History sensitivity allergic reaction hormonal contraceptive . 26 . Unwilling unable comply study protocol</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Lipoproteins</keyword>
	<keyword>Apolipoproteins</keyword>
	<keyword>Insulin sensitivity</keyword>
	<keyword>Inflammation</keyword>
	<keyword>Clotting</keyword>
	<keyword>Antioxidant status</keyword>
	<keyword>Vascular reactivity</keyword>
	<keyword>Metabolism</keyword>
</DOC>